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Abstract Physiological stress response and oxidative
damage are factors for aging processes and, as such, are
thought to contribute to neovascular age-related macular
degeneration (AMD). Paraoxonase 1 (PON1) is an en-
zyme that plays an important role in oxidative stress and
aging. We investigated association of DNA sequence
variants (SNP) within the upstream regulatory region of
the PON1 gene with neovascular AMD in 305 patients
and 288 controls. Four of the seven tested SNPs
(rs705379, rs705381, rs854573, and rs757158) were
more frequently found in AMD patients compared to
controls (P00.0099, 0.0295, 0.0121, and 0.0256, respec-
tively), and all but one (SNP rs757158) are in linkage
disequilibrium. Furthermore, haplotype TGGCCTC con-
ferred protection (odds ratio (OR)00.76, (CI)00.60–
0.97) as it was more frequently found in control individ-
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uals, while haplotype CGATGCT increased the risk
(OR01.55, CI01.09–2.21) for AMD. These results were
also reflected when haplotypes for the untranscribed and
the 5′untranslated regions (5′UTR) were analyzed sepa-
rately. To assess haplotype correlation with levels of gene
expression, the three SNPs within the 5′UTR were tested
in a luciferase reporter assay. In retinal pigment
epithelium-derived ARPE19 cells, we were able to mea-
sure significant differences in reporter levels, while this
was not observed in kidney-derived HEK293 cells. The
presence of the risk allele A (SNP rs705381) caused an
increase in luciferase activity of approximately twofold.
Our data support the view that inflammatory reactions
mediated through anti-oxidative activity may be relevant
to neovascular age-related macular degeneration.
Keywords Paraoxonase 1 . Gene regulation . SNP
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Introduction
Age-related macular degeneration (AMD) is a pro-
gressive degenerative disease, which in its advanced
stages leads to severe visual impairment. It is the
major cause of loss of vision in elderly patients in
developed countries (Deangelis et al. 2011). Advanced
stages of AMD manifest either as atrophic changes in
the macula (dry/atrophic/nonexudative AMD) or as cho-
roidal neovascularization (wet/neovascular/exudative
AMD). Although the neovascular AMD represents only
10–20 % of all AMD cases, it accounts for the vast
majority of cases with severe and rapid vision loss
(~90 %) (Jager et al. 2008).
The etiologic complexity of AMD arises from an
interplay of genetic and environmental factors. Recent
progress in AMD genetics has established several impor-
tant risk loci, among them the complement factor
H (CFH) on chromosome 1 (1q31) (Edwards et al.
2005; Hageman et al. 2005, 2006; Hughes et al. 2006;
Klein et al. 2005; Li et al. 2006) and the age-related
maculopathy susceptibility 2 (ARMS2/HTRA1) on chro-
mosome 10 (10q26) (Dewan et al. 2006; Jakobsdottir
et al. 2005; Rivera et al. 2005; Schmidt et al. 2006;
Tanimoto et al. 2007; Weger et al. 2007; Yang et al.
2006). Both loci combined are thought to account for
more than 50 % of AMD cases (Edwards et al. 2005;
Klein et al. 2005; Maller et al. 2006; Swaroop et al. 2007;
Thakkinstian et al. 2006). Their association with AMD
has been replicated across multiple ethnic groups world-
wide and further validated through a meta-analysis of
whole genome scans (Fisher et al. 2005). The discovery
of CFH as a genetic risk factor for AMD was supported
by functional studies revealing a role of the alternative
complement pathway in drusen formation (Hageman et
al. 2005). Following the discovery of genetic susceptibil-
ity loci, an impressive number of further genes has been
reported that either increase or lower the risk towards
AMDdevelopment (Katta et al. 2009). Despite the strong
associations established, it is still not possible to predict
the onset or course of AMD (Swaroop et al. 2007).
Hence, it is necessary to identify other genes involved
in the pathogenesis and understand their interactions.
To date, several additional candidate genes have been
studied for their association with AMD, including lipid
metabolism and oxidative stress genes (APOE (Baird et
al. 2004b; Pang et al. 2000),VLDLR (Conley et al. 2005;
Haines et al. 2006), LRP5 (Kloeckener-Gruissem et al.
2011), LRP6 (Haines et al. 2006), PON1 (Baird et al.
2004a; Brion et al. 2011; Esfandiary et al. 2005; Ikeda et
al. 2001; Pauer et al. 2010), LIPC (Neale et al. 2010),
and SOD2 (Gotoh et al. 2008; Kimura et al. 2000).
Discordant results across multiple studies indicate the
existence of additional factors that influence the devel-
opment of AMD in different populations.
Oxidative stress is implicated in the development of
AMD (AREDS 2001; Beatty et al. 2000; Khandhadia
and Lotery 2010); thus, identification of enzymes con-
ferring antioxidant protection is of interest. During the
last decade, paraoxonase 1 (PON1), an enzyme with
antioxidant properties, has been extensively investigated
in several disorders, including age-related pathologies
such as hyperlipidemia, atherosclerosis, coronary artery
disease, metabolic syndrome, type 2 diabetes, as well
as Alzheimer's disease (Androutsopoulos et al. 2011;
Mackness et al. 1998b, c; Paragh et al. 1998; Senti et
al. 2003). PON1 is a protein mainly synthesized in the
liver, and most studies have focused their analysis on
this fact. The enzyme is secreted into the blood where it
binds high-density lipoprotein (HDL) (Aviram 2004).
One of the functions of PON1 is to protect low-density
lipoprotein (LDL) from oxidative damage and to inacti-
vate oxidized LDL by hydrolyzing its oxidized phos-
pholipids (Deakin and James 2004).
PON1 serum concentration and activity are highly
variable across the general population (Deakin and
James 2004). This variability is attributed to environmen-
tal factors, such as smoking, diet, alcohol consumption,
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but also to the genetic polymorphisms in the PON1 gene.
There are two annotatedmissense SNPswithin thePON1
coding region: p.L55M (rs854560), where the major
allele L leads to elevated PON1 protein levels, and
p.Q192R (rs662), affecting substrate specificity as well
as enzyme activity (Garin et al. 1997; Humbert et al.
1993). These two missense polymorphisms affect also
the ability of HDL to protect LDL from oxidative mod-
ifications, with MM/QQ genotype being most effective
(Mackness et al. 1998a). The level of PON1 concentra-
tion in serum is also affected by sequence variants within
the promoter of the PON1 gene. In particular, the C allele
at position −107 (SNP rs705379) yields the highest level
of PON1 in the serum among all alleles that have been
investigated so far (Leviev and James 2000).
The antioxidant properties of PON1 stimulated re-
search for association of DNA sequence variants within
the PON1 coding region and AMD (Baird et al. 2004a;
Brion et al. 2011; Esfandiary et al. 2005; Ikeda et al.
2001; Pauer et al. 2010). Much focus has been on
studying the effects of the two above-mentioned poly-
morphisms, p.L55M and p.Q192R. In a Japanese AMD
patient cohort, the 55L and the 192R variants were
found more frequently (Ikeda et al. 2001), while in one
Caucasian cohort, the 55Q variant was associated with
the disease (Pauer et al. 2010). This association could
not be confirmed in further three Caucasian patient
groups suggesting the influence of other factors as well
(Baird et al. 2004a; Brion et al. 2011; Esfandiary et al.
2005). No information has been published on associa-
tions of sequence variants within upstream regulatory
regions of the gene and diseases. It was our goal to
expand the knowledge of effects of PON1 gene sequen-
ces beyond protein isoforms and to investigate the in-
fluence of the upstream regulatory regions on AMD.We
report here the identification of protective and risk hap-
lotypes with effects on gene expression, which displays
cell-type specificity.
Materials and methods
Patients
Patients with neovascular AMD were diagnosed at the
Department of Ophthalmology at the University
Hospital Zurich. Inclusion criteria regarding age,
visual acuity, and lesion type (minimally classic, pre-
dominantly classic, and occult) were based on the
MARINA (Rosenfeld et al. 2006) and ANCHOR
(Brown et al. 2006) trials. The patients were given a
full explanation of the nature and purpose of the study.
The study was conducted according to the Declaration
of Helsinki and was approved by the local ethics
committee. Clinical and demographic description as
well as the analysis of several common AMD risk
factors of this patient cohort has been published pre-
viously (Kloeckener-Gruissem et al. 2011). Data from
305 neovascular AMD patients are reported in the
current study. The average age of the patients was
79.41 years (±6.97); female to male ratio, 1.95. All
were of European descent, living in Switzerland. DNA
of 288 individuals representing the general population
was used as the control group (Moskvina et al. 2005).
These individuals were not age-matched and did not
undergo clinical assessment for the present study. They
were of European descent, living in Switzerland. The
female/male ratio was 2.1.
Genotyping
Venous blood was collected in EDTA tubes, and ge-
nomic DNA was extracted as described (Kloeckener-
Gruissem et al. 2011). DNA concentration was adjusted
to 10 ng/μl. SNP genotyping was performed either by
DNA sequencing (primer 1 CCTCCCCGACTGGAC-
TAGG and primer 2 AGGGAGTGAGGAGGAC-
GAAG were used for genotyping SNPs rs705379,
rs705380, and rs705381; primer 3 CCAAAAGCCTT-
GAGAAGGAA and primer 4 TGCTCTAGGTGATG-
CATGTGwere used for genotyping SNPs rs854571 and
rs854572) or by TaqMan technology (SNPs rs854571,
rs854573, and rs757158), using ABI chemistry (Ap-
plied Biosystems, Inc. [ABI], Rotkreuz, Switzerland).
Sequencing primers were designed by Primer3 (v. 0.4.0;
http://frodo.wi.mit.edu/primer3, provided in the public
domain by Massachusetts Institute of Technology,
Cambridge, MA) and synthesized by Microsynth
(http://www.microsynth.ch; Balgach, Switzerland).
Annealing temperatures varied between 54 and 60 °C.
For PCR, 50-ng genomic DNA and primers were cycled
35 times, each cycle lasting 1 min. For TaqMan assay,
probes from ABI were used. Genotype calling was
performed on SDS2.2 software, ABI. The allele
calling of SNP assay was verified by DNA
sequencing analysis for 10 % of all samples,
yielding 100 % concordance. In addition, genotyping
of 10 % of all samples was repeated for each SNP.
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Selection of SNPs and haplotype analysis
Seven SNPs, namely rs705379, rs705380, rs705381,
rs854571, rs854572, rs854573, and rs757158 (Fig. 1
and Table 1), within PON1 gene (NG_008779.1) were
chosen for association studies based on the linkage dis-
equilibrium (LD) data in the HapMap Caucasion (CEU)
population panel, using a tagging criteria of R2>0.8.
Since there is no LD information available for SNPs in
the 5′UTR (rs705379, rs705380, and rs705381), we in-
cluded them in the analysis.
Individual haplotypes and their estimated population
frequencies were inferred using PHASE program,
v2.1.1 (http://stephenslab.uchicago.edu/software.html),
with all parameters set at the default values (Stephens
and Donnelly 2003; Stephens et al. 2001).
In silico analysis of 5′UTR variants on RNA folding
Putative RNA folding structures were predicted
using the Mfold online software with standard settings
(http://mfold.rna.albany.edu/?q0mfold/RNA-Folding-
Form) (Zuker 2003). RNA structures were predicted
for the PON1 transcript (transcript: PON1-001
ENST00000222381) containing eight possible combina-
tions of alleles at the SNPs within 5′UTR.
Cloning
A 400-bp fragment of PON1 exon 1 containing the 5′
UTR was PCR-amplified (primer 1 and primer 2) and
cloned into the intermediate pJET1.2/blunt cloning vec-
tor using the CloneJET PCR Cloning Kit (Fermentas
International Inc, Glen Burnie, MD, USA). Fragments
containing four of the eight possible haplotypes were
obtained directly through PCR from patients' genomic
DNA (CCA, CGA, CGG, and TGG; SNPs' order from
left to right, rs705379, rs705380, and rs705381). DNA
fragments containing the other four haplotypes were
obtained by site-directed mutagenesis with the primer
extension approach. For all substitutions, primer 1
and primer 2 served as outside flanking primers. Each
mutation was obtained using additional pairs of inside
primers (sequences are written from 5′to 3′) as primer 5
CCGACCCGGCGGGGAGGGGTGGGGCGG
GCC with primer 6 GCAGCGCCGATTGGCCC
GCCCCACCCCTCCC, primer 7 GGGGCTGA
CCGCAAGCCGCGCCTTCTGTGC with primer
8 GACCAGGTGCACAGAAGGCGCGGCT
TGCGG, primer 9 GGGGCTGACCGCAAGC
CACGCCTTCTGTGC with primer 10 GACCAGGTG
CACAGAAGGCGTGGCTTGCGGTC, and primer 11
TGGTCGGCCCAGCTAGCTGCCGACCCGGCGGG
with primer 12 CCACCCCTCCCCGCCGGGTCGG
CAGCTAGC. Subsequently, the PON1 fragments repre-
senting each of the haplotype were cloned into pGL3-
Control vector (Promega, Madison, WI, USA). In the
first step, PCR reaction was performed to create aHindIII
restriction site upstream of the three 5′UTR SNPs using
primer 2 and primer 13 TATAAGCTTGTTGGAAG
GAGCAAAATG. In the second step, 238-bp fragments
spanning from the constructed HindIII site to the trans-
lational start codon ATG (NcoI site) were cloned into the
pGL3-Control vector using HindIII and NcoI restriction
enzymes (Fermentas). DNA sequences of all constructs
were verified by Sanger sequencing.
Expression studies
HEK293 cells were seeded on 24-well plates (105cells/
well) in 1 ml DMEM, 10 % FBS, and 1 % penicillin/
streptomycin and incubated under standard conditions
(37 °C, 5 % CO2). After 24 h, cells were transfected
using 1.5-μl branched polyethylenimine, PEI (1 μg/μl),
600-ng pFirefly construct, and 15-ng pRenilla construct
per well. Twenty-four hours later, the cells were har-
vested, and luciferase activities were analyzed using
Dual-Glo Luciferase Assay System according to the
protocol provided by Promega and measured on a Bio-
Tek Synergy microplate reader (BioTek Instruments,
Fig. 1 Schematic representation of the PON1 gene. Positions of
SNPs that were analyzed in this study are printed in bold. They
map to the upstream untranscribed region (UUR) and the 5′un-
translated region (5′UTR). SNPs in exon 3 (Ex3), exon 6 (Ex6),
and exon 9 (Ex9), investigated by other groups, are printed in
italics (Baird et al. 2004a; Brion et al. 2011; Esfandiary et al. 2005;
Ikeda et al. 2001; Pauer et al. 2010)
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Winooski, VT, USA). Data were normalized for trans-
fection efficiency by Renilla luciferase activity. The ex-
periment was performed three times with three replicates
each. ARPE19 cells (ATCC, Manassas, VA, USA) were
seeded on 24-well plates (8×104cells/well) in 1 ml
DMEM, 10 % FBS, 1 % penicillin/streptomycin, and
7.5 % Na2CO3 and cultured under standard conditions
(37 °C, 5 % CO2). Twenty-four hours later, transfection
was performed; for each well, 0.75-μl X-tremeGENE
9 transfection reagent (Roche Diagnostics, Indianapolis,
IN, USA), 250-ng pFirefly construct, and 6.25-ng pRe-
nilla construct were used. Luciferase activities were
measured and analyzed 24 h after transfection as
described above. The experiment was repeated four
times. Three of these repeats included three technical
replicates while one of them included eight.
Statistical analysis
Pairwise LD analysis was performed on phased haplo-
type data generated from the control group according to
the following formulas: R20D2/(pA1pA2pB1pB2 ), where
D0pA1B1pA2B2−pA1B2pA2B1; D′0D/Dmax, with Dmax0
min(pA1pB2, pA2pB1) if D>0 and Dmax0min(−pA1pB1, -
pA2pB2) ifD<0 (Mueller 2004). For association studies,
odds ratios and significance were calculated using 2×2
contingency table provided on an open access Internet
portal (http://faculty.vassar.edu/lowry/odds2x2.html).
Odds ratios were displayed with 95 % confidence inter-
vals and Chi-square and P values according to Pearson.
Statistical significance was assumed at P<0.05. For
expression studies, eight technical replicas were mea-
sured and averages with confidence intervals at 95 %
were computed. Fold-change differences were deter-
mined after normalizing the data to those obtained for
the TCG haplotype. This haplotype was chosen because
it yielded the lowest luciferase activity in the ARPE19
cell line. The Shapiro–Wilk test was applied to assess
normal distribution of the data. For statistical analysis,
the two-tailed t test was used.
Results
Linkage disequilibrium revealed two DNA blocks
within the upstream regulatory region of PON1
Linkage disequilibrium data are crucial for the design of
association studies. If two SNPs share high linkage
disequilibrium, with R2>0.8 one of them can be used
as tagged SNP. The region of PON1 investigated in our
study contains seven annotated SNPs (Fig. 1 and
Table 1). LD data on the HapMap website are available
only for four of them (rs854571, rs854572, rs854573,
and rs757158). To complete this information, we per-
formed LD analysis on phased genotype data of the
control individuals (Table 2). Our analysis confirms
already annotated data in a larger group of individuals
(haplotype number n0500 in our study, n0224 in Hap-
Map) and also provides pairwise R2 and D′ values for
SNPs which are not included in HapMap. Among the
seven analyzed SNPs, six belong to one haplotype block
Table 1 Allele frequencies of SNPs in the upstream regulatory region of PON1
Marker Major/minor allele Position Region MAF P value OR CI (95 %)
HapMap AMD (n0305) Controls (n0288)
rs705379 T/C −107 5′UTR 0.425 0.517 0.440 0.0099 1.36 1.08–1.73
rs705380 G/C −126 5′UTR 0.042 0.056 0.044 0.3566 1.29 0.75–2.21
rs705381 G/A −162 5′UTR 0.167 0.253 0.199 0.0295 1.37 1.03–1.81
rs854571 C/T −831 UUR 0.302 0.284 0.257 0.3009 1.14 0.89–1.49
rs854572 C/G −908 UUR 0.425 0.471 0.419 0.0759 1.23 0.98–1.56
rs854573 T/C −1075 UUR 0.230 0.255 0.194 0.0121 1.42 1.08–1.88
rs757158 C/T −1740 UUR 0.376 0.444 0.380 0.0256 1.30 1.03–1.64
Comparison between patients with neovascular AMD (n0305) and control individuals (n0288). Three SNPs map to the 5′untranslated
region while four of the SNPs lie within the upstream untranscribed region (Fig. 1). Minor allele frequencies for a Caucasian population
were taken from the HapMap website (http://www.hapmap.org) and were calculated for our patient (AMD) and control groups.
Statistical analyses are displayed as odds ratios (OR) with confidence intervals (CI) and P values, with α00.05
5′UTR 5′untranslated region, UUR upstream untranscribed region, MAF minor allele frequencies
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as they revealed high pairwise D′ values (rs705379,
rs705380, rs705381, rs854571, rs854572, and
rs854573). SNP rs757158 belongs to a separate haplo-
type block (Fig. 2). Among the analyzed SNPs, only
two pairs (rs705381 with rs854573, and rs854572 with
rs757158) fulfill tagging criteria of R2>0.8 (Table S1).
Association studies showed risk and protection
potential for AMD
Genotypes of seven SNPs within regulatory, non-coding
regions of the PON1 locus were determined from 305
patients with neovascular AMD and compared to those
from 288 control individuals (Table 1). The patients'
AMD phenotype has been reported in detail previously
(Kloeckener-Gruissem et al. 2011). Three SNPs within
the 5′UTR and four SNPs within the upstream untran-
scribed region (UUR) (Fig. 1) were genotyped and
analyzed. Note that as the transcriptional promoter re-
gion has not been defined experimentally, we chose to
name this region “UUR”, rather than “promoter region”.
Statistically significant association was found at two
SNP loci within the 5′UTR and two within the UUR:
rs705379 (OR01.36, CI01.08–1.73, P00.0099),
rs705381 (OR01.37, CI01.03–1.81, P00.0295),
rs854573 (OR01.42, CI01.08–1.88, P00.0121), and
rs757158 (OR01.30, CI01.03–1.64, P00.0256)
(Table 1).
To strengthen the significance of the association, we
included analyses of haplotypes. For the seven SNP
haplotypes (rs705379 at −107, rs705380 at −126 and
rs705381 at −162, rs854571 at −831, rs854572 at −908,
rs854573 at −1075, and rs757158 at −1740), PHASE
predicted 18 different combinations. Haplotypes with
fewer than five counts in PHASE (11 haplotypes) were
not taken into account for statistical analyses. The haplo-
type TGGCCTC, comprising exclusively major alleles,
was more frequently found in the control group, suggest-
ing a protective function (OR00.76, CI00.60–0.97, P0
0.0293), whereas the haplotype CGATGCT was more
frequent in AMDpatients (OR01.55, CI01.09–2.21,P0
0.0141), posing a risk for the disease (Table 2). Similar
results were found when SNPs from the 5′UTR and the
upstream untranscribed region (UUR) were analyzed
separately. The PHASE program revealed the presence
of four possible haplotypes for SNPs in the 5′UTR (TGG,
CGG, CGA, CCA; order of SNPs from left to right,
rs705379 at −107, rs705380 at −126, and rs705381 at
−162). Carriers of the haplotype TGG, representing the
major alleles within a population, were more frequently
found in the control group compared to the patient group,
and, hence, this haplotype confers a protection against
AMD (OR00.72, CI00.57–0.91,P00.0063), while con-
versely the haplotype CGA indicates a risk for AMD
(OR01.35, CI00.99–1.85, P00.0564) (Table 3). For the
four SNPs in the UUR, PHASE predicted seven different
haplotypes. Three haplotypes showed statistically signif-
icant differences between patient and control group
Table 2 Haplotype analysis for all seven SNPs
Haplotype AMD
(n0556)
n (%)
Controls
(n0500)
n (%)
P value OR CI (95 %)
TGGCCTC 264 (47.5) 271 (54.2) 0.0293 0.76 0.60–0.97
CGGCGTT 100 (18.0) 74 (14.8) 0.1637 1.26 0.91–1.75
CGATGCT 94 (16.9) 58 (11.6) 0.0141 1.55 1.09–2.21
CCATGCT 25 (4.5) 22 (4.4) 0.9203 1.02 0.57–1.84
CGGCCTC 26 (4.7) 18 (3.6) 0.3833 1.31 0.71–2.43
CGGTGTT 17 (3.1) 25 (5.0) 0.1069 0.60 0.32–1.12
CGATGCC 12 (2.2) 14 (2.8) 0.5023 0.77 0.35–1.67
SNP order for each haplotype, from left to right is as follows: -107,
-126, -162, -831, -908, -1075, and −1740. Haplotype counts (n)
and percentages (%) are given. Haplotypes with less than five
counts in PHASE were not taken into account for statistical
analysis. Odds ratios (OR) with confidence intervals (CI) and P
values (alpha00.05) are shown
Fig. 2 Pairwise linkage analysis of SNPs within the PON1 5′
UTR and upstream untranscribed region. R2 and D′ values are
depicted by the grayscale color code according to the legend.
Asterisks indicate SNPs for which no data are available on the
HapMap website
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frequencies (Table 3). The haplotype TGCT (rs854571 at
−831, rs854572 at −908, rs854573 at −1075, and
rs757158 at −1740) was associated with the disease
(OR01.44, CI01.07–1.95, P00.0165), whereas the
two haplotypes CCTC and TGTT were more frequently
found in the control group (OR00.79, CI00.63–0.99,
P00.0492 and OR00.48, CI00.27–0.84, P00.0092,
respectively) (Table 3).
Sequence variants in the 5′UTR alter predicted
structure of the PON1 mRNA
It is known that SNPs within the 5′UTR of genes can
affect its mRNA folding and consequently change trans-
lational efficiency (Zuercher et al. 2010). We simulated
the influence of the 5′UTR polymorphisms on secondary
RNA structures using the web server Mfold. RNA struc-
tures of the entire PON1mRNA (5′UTR, coding sequen-
ces, and 3′UTR) were predicted (Fig. 3). The predicted
structure of the reference sequence carrying the minor
alleles at three analyzed positions (−107C, -126C, and
-162A) was not different from that containing only one
major T allele at position −107 (Fig. 3a). In contrast,
predicted folding of RNA containing the major alleles
at position −126 and −162, singly, or in combination,
assumed a strikingly different structure (Fig. 3b). Based
on these bioinformatic predictions, we hypothesized that
SNPs within the 5′UTR of PON1 may have different
effects on protein synthesis.
AMD risk haplotype altered reporter gene activity
in cell culture
To correlate our association data and the structural pre-
dictions with potential effects on gene expression, we
designed experiments to test whether different PON1 5′
UTR haplotypes influence luciferase reporter gene ex-
pression in cell culture. We generated the eight possible
haplotypes in DNA constructs, containing the PON1 5′
UTR region fused to the Luciferase coding region, both
transcribed from the SV40 promoter. Since tissue-
specific effects on gene expression are likely to occur,
we included two different cell lines in this test: the
embryonic kidney-derived cell line HEK293 and the
retinal pigment epithelium-derived cell line ARPE19.
Both cell lines were transiently transfected with the
various PON1 5′UTR haplotypes in front of the lucifer-
ase reporter. In ARPE19 cells, we found statistically
significant differences in luciferase levels (Fig. 4). To
assess contribution of each individual SNP to increased
protein expression, we performed a pairwise compari-
son of luciferase levels between haplotypes differing at
only one position (Table 4). This analysis revealed that
SNP rs705381 at position −162 is mostly responsible for
Table 3 Haplotype analysis of the upstream untranscribed and untranslated region
Region Haplotype AMD n (%) Controls n (%) P value OR CI (95 %)
5′UTRa
TGG 280 (48.4) 297 (56.7) 0.0063 0.72 0.57–0.91
CGG 150 (26.0) 121 (23.1) 0.2713 1.17 0.89–1.54
CGA 116 (20.1) 82 (15.6) 0.0564 1.35 0.99–1.85
CCA 32 (5.5) 24 (4.6) 0.4708 1.22 0.71–2.10
UURb
CCTC 308 (52.4) 320 (58.2) 0.0492 0.79 0.63–0.99
TGCT 128 (21.8) 89 (16.2) 0.0165 1.44 1.07–1.95
CGTT 109 (18.5) 87 (15.8) 0.2253 1.21 0.89–1.65
TGTT 19 (3.2) 36 (6.5) 0.0092 0.48 0.27–0.84
TGCC 19 (3.2) 17 (3.1) 0.8875 1.05 0.54–2.04
Four haplotypes in the 5′untranslated region (5'UTR) and five haplotypes in the upstream untranscribed region (UUR) were analyzed in our
patient and control population. The order of SNPs, from left to right is −107, -126, and −162 (5′UTR) and −831, -908, -1075, and −1740
(UUR). Haplotype counts (n) and percentages (%) are given. Odds ratios (OR) with confidence intervals (CI) and P values (alpha00.05) are
shown. Haplotypes with fewer than five counts in PHASE were not taken into account for statistical analysis
a AMD, n0578; controls, n0524
b AMD, n0588; controls, n0550
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the observed difference in luciferase activity. The pres-
ence of the minor allele A leads to increase in the
reporter activity up to 2.1-fold. Small contribution to
the protein expression regulation has been found for two
other SNPs (rs705379 at −107, and rs705380 at −126),
with minor allele C at position −107 and minor allele C
at position −126, causing up to 1.6- and 1.4-fold
increase in luciferase level, respectively. Interestingly,
in HEK293 cells, we did not find statistically significant
differences in luciferase activity between the different
constructs (data not shown), supporting our initial as-
sumption of cell-specific effects on gene expression.
Discussion
This is the first report to show association of SNPs in the
upstream regulatory region of PON1 with neovascular
AMD. Previous studies have investigated association
between SNPs within the PON1 coding region and
AMD (Brion et al. 2011; Baird et al. 2004a; Esfandiary
et al. 2005; Pauer et al. 2010; Ikeda et al. 2001). The
focus was on twomissense polymorphisms p.L55M and
p.Q192R. Conflicting results were obtained when com-
paring different patient cohorts; while association with
wet AMD has been found for both variants in a Japanese
population (Ikeda et al. 2001), only the p.Q192R variant
was associated in only one of the four Caucasian cohorts
(Pauer et al. 2010). Furthermore, in the Japanese study,
the arginine at position 192 of the PON1 protein has
been found more frequently in the patient group,
whereas in Caucasians, the glutamine (192Q) variant
has been associated with the disease. Possible explana-
tions encounter different allele frequencies in the differ-
ent ethnic groups but also a diverse phenotype of AMD
(Bird 2003; Oshima et al. 2001). Specifically for SNP
p.Q192R in Caucasians, the minor variant is R with a
frequency of 0.332, whereas in Japanese, the arginine is
the major variant with an allele frequency of 0.706
(HapMap). As there is no linkage disequilibrium between
p.Q192R variant and the promoter polymorphisms (Lev-
iev and James 2000) (HapMap), a direct comparison
between our data and those reported from other Cauca-
sian patient cohorts, which examined p.Q192R (Baird et
al. 2004a; Brion et al. 2011; Esfandiary et al. 2005; Pauer
et al. 2010) is not meaningful.
In contrast to p.Q192R, the variant 55L is in linkage
disequilibrium with the allele -107C (Leviev and James
2000), which is associated with AMD in our study. It has
been shown that these two alleles lead to increased levels
of PON1 in serum (Leviev and James 2000). Thus, it
may be difficult to understand how higher levels of a
protein that is known to have antioxidant properties can
be associated with AMD. For a possible explanation, we
would like to emphasize that variant p.L55M has been
reported to affect PON1 activity towards lipid peroxides,
with the LL genotype being less effective than MM at
protecting LDL against oxidation (Mackness et al.
1998a). Since alleles at position -107C and -162A are
in linkage disequilibriumwith variant 55L, they are likely
to be also associated with the less effective protection
against oxidation, thus can confer the risk for AMD and
Fig. 3 Predicted PON1
mRNA foldings. a The
structure represents folding
of the PON1 mRNA
containing the minor alleles
CCA in the 5′untranslated
region. It was indistinguish-
able from the allele combi-
nation TCA. b The structure
depicts mRNA folding in the
presence of the other six
allelic combinations: CGA,
TGA, CCG, TCG, CGG, and
TGG (SNP order from left to
right, -107,-126, and −162)
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be responsible for increased oxLDL levels (Ikeda et al.
2001) in AMD patients.
To strengthen the significance of the association found
with individual SNPs, we performed haplotype associa-
tion analysis. We discovered two seven-SNP haplotypes
associated with AMD. The most abundant haplotype
(54.2 % in controls), TGGCCTC, was more frequently
found in controls conferring a protection against AMD,
whereas haplotype CGATGCT was a risk factor. Inter-
estingly, the two haplotypes CGATGCC and CCATGCT,
each differing at only one position in comparison to
CGATGCT, appeared not to be associated with the dis-
ease. These data imply a possible interplay between the
analyzed loci and underlines the importance of haplotype
analysis to assess risk factors. Similar results were
obtained when analyzing haplotypes within the 5′UTR
and UUR separately.
It is known that sequence variants within the 5′UTR
can regulate gene expression at the level of protein
translation. We asked whether this would also apply
to the PON1 gene. To support our notion, we performed
in silico RNA folding predictions for the different
allelic combinations and found that the presence of the
major alleles for two SNPs in the 5′UTRwould lead to a
striking difference in the folding properties of the entire
PON1 transcript. Furthermore, these alleles also appear
to have an effect on reporter gene expression as mea-
sured by luciferase enzyme activity. Specifically,
in the retinal pigment epithelium-derived cell line
ARPE19, the protective TGG haplotype yielded the
lowest level of luciferase activity, while the CCA hap-
lotype resulted in the highest reported expression levels.
When comparing those haplotypes differing at only one
position, we discovered that the SNP at position −162
provided the largest contribution, with the A nucleotide
causing up to 2.1-fold increase in luciferase reporter
activity. Previous reports have shown that this allele
Fig. 4 Fold increase of
luciferase activity for the
eight PON1 5′UTR haplo-
types in ARPE19 cells. The
luciferase activity of the re-
porter construct containing
the TCG haplotype was set
to 1. SNP order in haplo-
types from left to right: -
107, -126, and −162. Error
bars show confidence inter-
vals, CI095 %. Displayed
are results from a represen-
tative experiment with eight
technical replicates
Table 4 Effects of 5′UTR haplotypes on luciferase reporter
activity
SNP Haplotypea Fold increase
in luciferase
activityb
P valuec
1 2
−107 CCA TCA 1.4 <0.001
CCG TCG 1.4 0.016
CGA TGA 1.3 0.030
CGG TGG 1.0 0.984
−126 CCA CGA 1.6 <0.001
CCG CGG 1.2 0.094
TCA TGA 1.4 <0.001
TCG TGG 0.9 0.242
−162 CCA CCG 2.1 <0.001
CGA CGG 1.6 <0.001
TCA TCG 2.0 <0.001
TGA TGG 1.2 0.030
The comparison is based on haplotypes that differ at a single
position. Displayed are results for a representative experiment
shown in Fig. 4
a SNP order in haplotype, from left to right is −107, -126,
and −162
b Fold increase in luciferase activity, haplotype 1 versus
haplotype 2
c Two-tailed t test
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caused up-regulation of transcription in cultured kidney
and liver cell lines (Brophy et al. 2001). These data,
together with our findings, indicate that the position at
−162 has regulatory function at both steps of gene ex-
pression, transcription, as well as translation. Alternative-
ly, a sole effect on transcription of the luciferase reporter
cannot be excluded. In our study, the two other investi-
gated SNPs at positions −107 and −126 caused only
minor changes in luciferase activity. In the literature, no
effect of the SNP at −126 has been reported, but the
minor allele C at position −107 has been shown to
increase transcription of a luciferase reporter gene in
HepG2 and HEK293 cells (Brophy et al. 2001). Taking
these data together, we conclude that the three SNPs
support different activities for PON1 gene expression.
It is important to note that the luciferase reporter
assays did not yield the same results in the two different
cell lines tested. As cell and tissue-specific regulation of
gene expression is a well-known phenomenon, it is not
surprising that gene expression control potential within
the 5′UTR of PON1 is manifested in ARPE19 cells, but
not in HEK293 cells. The latter cells, derived from kid-
ney, do not seem to be implicated in the AMD pathology,
while ARPE19 cells, derived from retinal pigment epi-
thelium, do (Kinnunen et al. 2012). In this context, it is
plausible that the relevant SNP at position −162 exerts a
cell type-specific effect in favor of AMD. Since Pon1 is
expressed in the retinal pigment epithelium in mice (data
not shown), further studies will provide crucial informa-
tion to clarify these assumptions.
A number of factors such as blood pressure, usage
of antihypertensive medication, blood cholesterol, or
blood levels of high-density lipoprotein were shown to
be associated with the development of neovascular
AMD (Hyman et al. 2000). As the mean age of the
population studied here is 79.5 years, it can be
expected that some of the factors (e.g., increased
arterial blood pressure) are present in the study
population—assumingly randomly distributed across
the participants. An influence of the proposed cardio-
vascular risk factors on the outcome of the treatment
of neovascular AMD using ranibizumab has not yet
been shown. Hence, it remains speculative whether or
not such risk factors may have had an impact in the
current study population and the reported outcomes.
Many open questions remain on the involvement of
PON1 in AMD pathology. As our patients were diag-
nosed with the end stage neovascular AMD, our results
cannot account for a potential role of PON1 as a trigger
for the onset of AMD or as an accelerator during the
progression of the disease, or maybe both. Our and other
previous association studies imply the involvement of
PON1 at the late stage of the disease. An alternative
mechanism may exist, where PON1 enzyme changes
are secondary to other events, present at early stages of
AMD. For example, paraoxonase activity in serum is
decreased in AMD patients. As AMD is considered to
be a chronic inflammatory disease and the PON1 tran-
scription levels in liver are known to be down-regulated
in response to infections, it seems feasible that PON1
down-regulation and decreased activity are the outcome
of primarily inflammation events. Cross talk between
PON1 levels and inflammatory response could be medi-
ated by the oxLDL, which can induce expression of
genes involved in an inflammation by stimulating various
transcription factors (Maziere and Maziere 2009). Our
results provide insights in the action of PON1, but further
investigation is required for a deeper understanding of the
contribution of PON1 in the pathology of AMD.
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